Published in Biotech Law Weekly, July 6th, 2007
These improvements to the VEBA's prescription drug benefits will place a flat co-payment on drugs that previously had a percentage co-pay. Plan participants will now pay as little as $10 for preferred generic drugs and up to $50 for specialty drugs. The potential savings for plan participants will be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.